A Glass of MAKO Grigio

In this video, health care bureau chief Brenton Flynn touches on the under-discussed subject of transparency in the data companies release in their quarterly earnings reports. While MAKO Surgical (Nasdaq: MAKO  ) has excellent transparency ratings in comparison with a company like Amazon (Nasdaq: AMZN  ) , which is known for being a bit stingy with some of its data, there's one piece of MAKO data on Flynn's wishlist: vintage. Like a fine wine, Flynn not only wants to know how MAKO's surgical systems are being used now, he wants to know how they age over time, and how the utilization of the older systems stacks up against the newer ones. Seeing good numbers here would be good for investors and MAKO's clients, and that's good for everyone.

MAKO has some good numbers to show us, and because of the recent market sell-off of MAKO Surgical shares, we need to see them. The company's recent downtick has many wondering whether the potential growth prospects of the robotic surgery company make this stock a buy or a stock to stay away from. To answer this question, Fool.com analyst and MAKO expert David Meier has authored a premium research report covering all of the must-know details on the company, including key areas to watch and risks looming in the future. As an added bonus, David will keep you informed with a full year of updates and guidance on MAKO Surgical as news breaks. Click here now to learn more and start reading.